1. Home
  2. KF vs AVXL Comparison

KF vs AVXL Comparison

Compare KF & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Korea Fund Inc. (The) New

KF

Korea Fund Inc. (The) New

HOLD

Current Price

$64.42

Market Cap

242.8M

Sector

Finance

ML Signal

HOLD

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

HOLD

Current Price

$3.22

Market Cap

237.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KF
AVXL
Founded
1984
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
242.8M
237.2M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
KF
AVXL
Price
$64.42
$3.22
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$22.00
AVG Volume (30 Days)
27.0K
960.1K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.69
$2.26
52 Week High
$81.94
$10.40

Technical Indicators

Market Signals
Indicator
KF
AVXL
Relative Strength Index (RSI) 57.78 58.91
Support Level $60.80 $2.93
Resistance Level $72.06 $3.50
Average True Range (ATR) 2.12 0.16
MACD 1.27 0.02
Stochastic Oscillator 98.74 63.62

Price Performance

Historical Comparison
KF
AVXL

About KF Korea Fund Inc. (The) New

Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and Others.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Share on Social Networks: